GLP-1 Pipeline Update: August 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid
Tirzepatide (Mounjaro, Zepbound) is a dual agonist that acts on both the GIP and GLP-1 receptors, a related but distinct mechanism
For where these oral and higher-dose options sit among the candidates now in development, see the 2026 GLP-1 clinical pipeline, part of the broader GLP-1 and metabolic disease picture
According to bmiMD's site, they source from licensed 503a compounding pharmacies, and the specific pharmacy depends on your state
Frequently Asked Questions Does injecting semaglutide at night instead of morning change how much weight I'll lose
Why Ozempic Isn't an Option at Klinic for Weight Loss While both Ozempic and Wegovy contain semaglutide, they have distinct uses